{"entity":{"id":"nct06259058","kind":"trial","name":"Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of liposomal irinotecan, cAPOX (capecitabine, oxaliplatin), fluorouracil (5-FU) and fLOT (5-FU, leucovorin, oxaliplatin, docetaxel) in pancreatic cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.","summary":"Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer is a phase 1/2, randomised interventional study registered as NCT06259058 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 96 participants, started 2024-04-01 and due to reach its primary completion in 2026-04-01. Interventions recorded: Irinotecan liposome injection; Oxaliplatin; 5-Fluorouracil; Leucovorin; SBRT. Conditions listed: Pancreatic Cancer. Primary outcome: R0 resection rate. Pancreatic eligibility wording from the registry: \"* Histologically or cytologically proven pancreatic ductal adenocarcinoma\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06259058","url":"https://clinicaltrials.gov/study/NCT06259058"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["borderline-resectable-pdac","resectable-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy","sbrt","topoisomerase-inhibitors"],"targets":[],"drugs":["liposomal-irinotecan","capox","fluorouracil","flot"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06259058","phase":"1/2","setting":"Evaluate the Efficacy and Safety of Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer: a Phase Ib/II, Multicenter, Open-label Trial","sponsor":"Tianjin Medical University Cancer Institute and Hospital","enrolled":96,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06259058/","neighbours":{"cancer":[{"id":"borderline-resectable-pdac","kind":"cancer","name":"Borderline resectable pancreatic ductal adenocarcinoma","route":"/cancers/borderline-resectable-pdac/"},{"id":"resectable-pdac","kind":"cancer","name":"Resectable pancreatic ductal adenocarcinoma","route":"/cancers/resectable-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"drug":[{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"},{"id":"flot","kind":"drug","name":"FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)","route":"/drugs/flot/"},{"id":"fluorouracil","kind":"drug","name":"Fluorouracil (5-FU)","route":"/drugs/fluorouracil/"},{"id":"liposomal-irinotecan","kind":"drug","name":"Liposomal irinotecan","route":"/drugs/liposomal-irinotecan/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}